Guerbet: David Hale appointed CEO of Guerbet as from January 1, 2020 to accelerate deployment of the Group’s strategy
December 18 2019 - 11:00AM
David Hale appointed CEO of Guerbet as
from January 1, 2020 to accelerate deployment of the Group’s
strategy
Villepinte (France), December 18th, 2019
(6 :00 pm CEST) – Guerbet’s Board of Directors
announces the appointment of David Hale as Chief Executive Officer
as from January 1, 2020.
Chief Commercial Officer and Group Executive
Committee member since February 2018, David Hale takes over the
position from Yves L’Epine, who has been CEO since end of 2011.
For 2019, Guerbet confirms expected sales up by
more than 3% with an EBITDA margin of around 14%, despite a
production halt in Dublin following technical incidents now
resolved. For 2020, the EBITDA margin is expected between 14 and
15%, down from the intermediate objectives of the GEAR 2023 plan.
However, with the appointment of David Hale, the Board of Directors
confirms the Company’s strategic ambition of the GEAR 2023 plan,
with the development in the interventional and augmented
intelligence imaging segments. In this regard, the Group will
communicate more precisely on the update of its strategic plan at
the end of the first half of 2020.
The decision of the Board of Directors to
replace Yves L’Epine comes in that context. Marie-Claire
Janailhac-Fritsch, chairwoman of the Board, said: « On behalf
of the Board, I salute the work accomplished by Yves L’Epine
throughout the last eight years, which resulted in the strong
growth of the Group’s financial indicators over the period as well
as his decisive contribution in the 2015 acquisition and subsequent
integration of the imaging division of Mallinckrodt. This
transformative transaction doubled the size of Guerbet. Since 2018,
the Group has adopted a diversification strategy, particularly in
interventional imaging and augmented intelligence imaging, and
wishes to accelerate the implementation of this strategy. We wish
David Hale all the best in his new role aimed at developing the
enterprise’s business ».
David Hale, 51, Franco-American, joined
Guerbet’s Executive Committee in February 2018 as Chief Commercial
Officer. His international career is characterized by strong
geographical mobility, particularly in the United States, France,
Germany and Switzerland, contributing to his ability to adapt and
succeed in different cultures. Prior to Guerbet, David Hale was
with the Boston Consulting Group and then with GE Healthcare,
where he spent most of his career in areas such as Service,
Software and Medical Devices.
About
Guerbet
Guerbet is a pioneer in the contrast-agent
field, with more than 90 years' experience, and is a leader in
medical imaging worldwide. It offers a comprehensive range of
pharmaceutical products, medical devices and services for
diagnostic and interventional imaging, to improve the diagnosis and
treatment of patients. With 8% of revenue dedicated to R&D,
Guerbet is a substantial investor in research and innovation.
Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps)
and generated €790 million in revenue in 2018. For more information
about Guerbet, please visit www.guerbet.com.
Communication
contacts
Guerbet Corporate
Communication
Financial Communication Alize
RP
ActifinCaroline Carmagnol
Christophe De Lylle+33 (0)6 64 18 99 59 /
guerbet@alizerp.com +33
(0)6 08 98 04 04 / cdelylle@actifin.fr
Guerbet (EU:GBT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Nov 2023 to Nov 2024
